Dave Fornell, DAIC Editor

Dave Fornell, Editor DAIC

Blog | Dave Fornell, DAIC Editor | November 08, 2013

The Hottest Topics and Technologies in Interventional Cardiology at TCT 2013

By Dave Fornell, DAIC editor

The Cardiovascular Research Foundation’s Transcatheter Cardiovascular Therapeutics (TCT) 2013 meeting brought many new insights about the latest cardiovascular technologies and treatment techniques. Among the hottest topics were transcatheter heart valve repairs, renal denervation to treat drug resistant hypertension, left atrial appendage (LAA) occluders to prevent stroke and eliminate warfarin therapy in atrial fibrillation patients, bifurcation stenting trials and techniques, new insights on anti-clotting agents, increasing use of ultrasound and intravascular imaging, new technologies for FFR lesion assessments, and the latest stent trial data.

I offer my editor’s choice for the most innovative new technologies presented in sessions and on the show floor in a video format.

For a video of the top meeting highlights, Herb Aronow, M.D., offers his views on some of the most interesting topics discussed in sessions.

The most exciting interventional device to enter the U.S. market a couple days prior to TCT was Abbott's MitraClip. We conducted a video interview with the lead author of the MitraClip FDA pivotal trial at TCT.

Here is a summary of some of the top news from TCT. You can click on any item to read the full story.

CoreValve shows outcomes as good or better that Sapien

CT-FFR shown to be comparable to invasive FFR

Dedicated Tryton bifurcation stent did not meet primary endpoint

Provisional vs. two-stent bifurcation therapy has similar outcomes

Data promising for first FDA drug-eluting balloon trial

Simplified, non-adenosine iFR compares favorably with standard FFR

Hypothermia for STEMI safe, but did not reduce infarct size

Thrombectomy does not improve outcomes in NSTEMI PCI

MitraClip trial data leads to FDA approvalVideo interview with lead author of study

Bioresorbable polymer coated stent equal to traditional DES

Boston Scientific’s Lotus TAVR valve meets primary endpoints in REPRISE II

Pre-hospital bivalirudin for STEMI improves outcomes

• Data from two trials (ARCTIC-INTERRUPTION and OPTIMIZE) shows short-duration DAPT is feasible

Genetic profiling for CYP2C19 antiplatelet agents improves outcomes

Transradial access lowers bleeding risks in women

In addition to these news items, listed below are more top trial summaries and new product releases.

Related Content

TCT 2016, TCT.16, main arena, late breaking trials
Feature | Cath Lab| September 28, 2016
September 28, 2016 — The Cardiovascular Research Foundation (CRF) has announced the 11 late-breaking trials and 16 fi
Avinger, U.S. Department of Veterans Affairs, VA, Lumivascular technology, FSS Contract Award
News | Optical Coherence Tomography (OCT)| September 27, 2016
Avinger Inc. recently announced the company has received an FSS Contract Award from the U.S. Department of Veterans...
News | Pharmaceuticals| September 26, 2016
Nearly 2 out of 5 people with diabetes who could benefit from statin therapy to lower their risk of future heart attack...
Bard, Lutonix 014 DCB, drug-coated balloon, six-month endpoint, FDA IDE trial
Technology | Drug-Eluting Balloons| September 26, 2016
C. R. Bard Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE...
smartphones, hospital tranfers, heart attack patients, JACC study, South Korea
News | Mobile Devices| September 23, 2016
Smartphone communication among medical teams at different hospitals can significantly reduce the time it takes for...
Robert M. Califf, FDA commissioner, future of cardiovascular medicine, JACC column
News | Business| September 23, 2016
Technology advances coupled with increased use of social media and personal devices could offer new possibilities for...
Medtronic, In.Pact Admiral drug-coated balloon, trial data, VIVA
News | Drug-Eluting Balloons| September 22, 2016
New data presented at the Vascular Interventional Advances (VIVA) conference demonstrated the durability, consistency...
4Tech, TriCinch TTVR, transcather tricuspid valve repair device, first implant
News | Heart Valve Technology| September 22, 2016
4Tech Inc. announced that its TriCinch device has been used in the world’s first-ever successful transcatheter...
Transesophageal Echo, TEE. Interventional echocardiography, interventional echo, Philips, CX50

Transesophageal echo (TEE) has become an essential part of the new transcatheter structrual heart therapies, giving rise to a new sub-speciality of interventional echocardiography.  

Feature | Cath Lab Navigation Aids| September 21, 2016 | Dave Fornell
The rapid growth of transcatheter structural heart procedures and the need for increased use of echocardiography as a
Sponsored Content | Videos | Inventory Management| September 21, 2016
With bundled payments putting increased pressure on hospitals to manage supply costs while providing quality patient
Overlay Init